

# Diagnostic Accuracy of Diffusion Weighted Imaging in Diagnosing Malignant Ovarian Lesions Keeping Histopathology as the Gold Standard

Tooba Rehman, Hussain Rashid Ihsan, Nosheen Sadiq, Tabassum Rasul, Hassan Tariq\*

Department of Radiology, Combined Military Hospital, Multan/National University of Medical Sciences (NUMS) Pakistan, \*Department of Histopathology, Combined Military Hospital, Multan/National University of Medical Sciences (NUMS) Pakistan

## ABSTRACT

**Objective:** To determine the accuracy of diffusion weighted imaging (DWI) and apparent diffusion coefficient (ADC) value in diagnosing malignant ovarian lesions.

**Study Design:** Cross-sectional study.

**Place and Duration of Study:** Department of Radiology, Combined Military Hospital, Multan Pakistan, from Jun 2024 to May 2025.

**Methodology:** A total of 58 patients were enrolled in this study. They were first subjected to DWI, and ADC values were calculated to categorize ovarian masses as benign/malignant. Later, all patients underwent excision of the mass, followed by histopathological categorization of the mass as benign or malignant. The diagnostic accuracy, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of DWI in diagnosing malignant ovarian lesions were determined.

**Results:** Mean age was  $50.03 \pm 6.68$  years, while mean BMI was  $26.44 \pm 2.40$  kg/m<sup>2</sup>. ADC values of malignant tumors showed a mean of  $1.08 \times 10^{-3}$  mm<sup>2</sup>/s  $\pm 0.014$ , with a *p*-value  $< 0.001$  (highly statistically significant). Sensitivity 83.33%, specificity 80.00%, PPV 95.24%, NPV 50%, and overall diagnostic accuracy 82.76% of DWI MRI in differentiating benign and malignant ovarian masses.

**Conclusion:** DWI with ADC value has good sensitivity and specificity in differentiating benign from malignant ovarian lesions.

**Keywords:** Apparent diffusion coefficient (ADC), Diagnostic accuracy, Diffusion weighted imaging, Ovarian mass, Sensitivity, Specificity.

**How to Cite This Article:** Rehman T, Ihsan HR, Sadiq N, Rasul T, Tariq H. Diagnostic Accuracy of Diffusion Weighted Imaging in Diagnosing Malignant Ovarian Lesions Keeping Histopathology as the Gold Standard. *Pak Armed Forces Med J* 2026; 76(Suppl-6): S885-S889.

DOI: <https://doi.org/10.51253/pafmj.v76iSUPPL-6.13560>

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by-nc/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

## INTRODUCTION

Ovarian carcinoma accounts for significant morbidity and mortality worldwide. About 5% of female cancer patients die from ovarian cancer, which accounts for 2.5% of all gynaecological cancers.<sup>1</sup> The precise prevalence of ovarian cancer in Pakistan is unclear. The incidence in Asian countries is 2–6.5 new cases per 100,000 women annually.<sup>2</sup> The three types of primary ovarian cancers are germ cell tumours, sex cord-stromal tumours, and epithelial-stromal tumours, which account for 90% of cases.<sup>3</sup> The endometrium, pancreas, gastrointestinal system, and breast are the most common sites of origin for secondary ovarian tumours. The majority of them exhibit the same histological and clinical characteristics as the main tumours.<sup>4</sup>

Intravenous (IV) contrast combined with pelvic and abdominal CT is the preferred test for

determining the extent of disease before surgery. Additionally, it can forecast if surgical cytoreduction will be successful.<sup>5</sup> However, in CT patients typically receive far larger doses of ionising radiation.<sup>6</sup> By carefully choosing pulse sequences, MRI can be utilised to visualise anatomy and evaluate physiological parameters and metabolic activity.<sup>7</sup> The diffusivity of endogenous water molecules in a tissue is determined using MRI. ADC maps of water molecules can be created using DWI.<sup>8</sup> With a higher sensitivity of diffusion than traditional MRI, the optimal cutoff value of ADC to distinguish between benign and malignant lesions is estimated to be  $1.2 \times 10^{-3}$  mm<sup>2</sup>/s.<sup>9</sup> The only chance of a good cure rate for ovarian cancer is early and timely diagnosis. Regretfully, even though several biomarkers have emerged, there isn't a successful early diagnosis method.<sup>10</sup>

This study's primary goal is to evaluate the diagnostic accuracy of DWI in identifying malignant ovarian tumours using the quantitative ADC value

**Correspondence:** Dr Tooba Rehman, Department of Radiology, Combined Military Hospital, Multan Pakistan

Received: 14 Jun 2025; revision received: 19 Feb 2025; accepted: 03 Sep 2025

metric. Patients with ovarian cancer who have a relative or absolute contraindication to contrast material will benefit from early diagnosis and timely treatment.

### METHODOLOGY

This cross-sectional (validation) study was carried out in Department of Radiology, Combined Military Hospital, Multan, Pakistan, from Jun 2024 to May 2025, after receiving Institutional Ethical Committee approval (EC 101/2024 dated 13 May 2024). Using the OpenEpi sample size calculator, version 3, a sample size of 55 was determined with a 95% confidence level, a 5% margin of error, and a 3.7% prevalence of ovarian cancer.<sup>11</sup> The chosen sample size was fifty-eight. Non-probability convenient sampling technique was employed.

**Inclusion Criteria:** This study included women aged 20 to 70 who were sent to the radiology department for MRIs of the abdomen and pelvis with DWI. After undergoing surgery at CMH Multan, these patients were able to acquire postoperative histopathology diagnostic results. These patients never had an adnexal mass biopsy or surgery before.

**Exclusion Criteria:** This study excluded pregnant women, patients who had previously undergone adnexal surgery or biopsy/histopathology, patients who were younger than 20 or older than 70, patients who were contraindicated for MRI, had no indication for surgery, or had already received radiation, chemotherapy, or any other treatment before an MRI test.

Following an informed written agreement, 58 women who met the inclusion criteria were enrolled. Age, BMI, parity, monthly menstruation irregularities, menopause status, and abdominal/pelvic discomfort were among the questions asked of each patient. The MRI equipment, Vantage Atlas 1.5 Tesla, Toshiba Japan, performed MRI with DWI on all patients in accordance with hospital procedure. For optimal image quality, patients were kept nil per os for at least three hours before MRI. Every patient had a full bladder and was resting supine. A consultant radiologist with at least five years of post-fellowship experience reported all of the MRIs. The ADC value of the solid component was assessed. If their ADC values on DWI were less than  $1.17 \times 10^{-3} \text{ mm}^2/\text{s}$ , they were considered malignant.<sup>9</sup> When bilateral ovarian masses were discovered, the mass with the most intricate shape was examined.

All of the patients had lesions surgically removed from the Obstetrics & Gynaecology department either by laparotomy or laparoscopy, and the specimens (ovarian mass, peritoneum, and lymph nodes) were transported to the histopathology department. A consultant histopathologist with at least ten years of post-fellowship experience evaluated each biopsy specimen and classified them as benign or malignant. For microscopic analysis, three to five biopsy specimen sections were stained using standard Haematoxylin and Eosin stain under both low and high fields. Cellularity, stromal invasion, pleomorphism, and the number of mitoses per ten high-power fields were all assessed in the sections. Cellular pleomorphism and stromal invasion were indicators of malignant lesions. The histopathologist was unaware that ovarian lesions might be classified by MRI. To evaluate the diagnostic accuracy of DWI in identifying malignant ovarian lesions, a histopathology report was obtained from the histopathology department and compared with an MRI DWI report.

Data was analyzed for age, BMI, and parity, and the mean and standard deviation. Monthly irregularities (oligomenorrhea/amenorrhea), menopause status, and pelvic/abdominal discomfort were measured for frequency and percentage. The purpose of the 2x2 contingency table was to ascertain DWI's precision in identifying cancerous ovarian lesions. To evaluate the diagnostic performance of the measured ADC value in identifying malignant ovarian lesions, a receiver operating characteristic (ROC) curve was created. AUC, or area under the curve, was computed. AUC >0.8 was regarded as good, while AUC > 0.9 as exceptional.<sup>12</sup> Associations between categorical variables (pain, oligomenorrhea, postmenopausal status) and histopathological diagnosis (benign vs malignant) were assessed using the Chi-square test. Fisher's Exact test was applied when the expected frequency in any cell was <5%. A statistically significant result was defined as a *p*-value < 0.05.

### RESULTS

The final analysis included 58 female patients. Most patients had BMIs between 25 and 30 kg/m<sup>2</sup>, with the mean age being 50.03±6.68 years and the mean BMI being 26.44±2.40 kg/m<sup>2</sup>. The median of parity value was determined to be 2.

During study, all patients were asked about their history of oligomenorrhea, abdominal/pelvic pain,

## Diagnosing Malignant Ovarian Lesions

and menopausal status. It was observed that 12.1% of patients had oligomenorrhea, a history of pain was present in 19% patients, and 63.8% patients were postmenopausal (Table-II).

**Table-I: Summary of participants' demographics (n=58)**

Variable	Value
Age in years (Mean± SD)	50.03±6.68
BMI in Kg/m <sup>2</sup> (Mean± SD)	26.44±2.40

BMI = Body Mass Index

**Table-II: Distribution based on the clinical parameters (n=58)**

Variable	Histopathology		p-value
	Benign (n=10)	Malignant (n=48)	
Oligomenorrhea (n=7)	Yes	2(20%)	0.592
	No	8(80%)	
Pain (n=11)	Yes	2(20%)	1.000
	No	8(80%)	
Menopause (n=37)	Yes	2(20%)	0.002
	No	8(80%)	

The mean ADC value of malignant tumours was  $1.08 \times 10^{-3} \text{ mm}^2/\text{s} \pm 0.014$ , with a minimum value of  $0.85 \times 10^{-3} \text{ mm}^2/\text{s}$  and a maximum value of  $1.35 \times 10^{-3} \text{ mm}^2/\text{s}$ . The benign masses' ADC values ranged from  $1.06 \times 10^{-3} \text{ mm}^2/\text{s}$  to  $2.12 \times 10^{-3} \text{ mm}^2/\text{s}$ , with a mean of  $1.62 \times 10^{-3} \text{ mm}^2/\text{s} \pm 0.112$ . It is clear from Table III that the mean ADC value for benign tumours was higher than that of malignant ones. ADC measurements were used to build an ROC curve, and Figure-1 shows that the area under the curve was 0.14.


**Table-III: Comparison of mean ADC values in benign and malignant ovarian lesions**

Parameter	Mean± SD	p-value
ADC Value	Benign $1.62 \times 10^{-3} \text{ mm}^2/\text{s} \pm 0.112$	<0.001
	Malignant $1.08 \times 10^{-3} \text{ mm}^2/\text{s} \pm 0.014$	

ADC - Apparent diffusion coefficient

In 42 cases, DWI confirmed the cancer diagnosis. In 48 cases, histopathology results verified cancer. Of the 42 patients with a DWI suspicion of cancer, 40 were true positives and 2 were false positives. Out of sixteen DWI-negative patients, eight patients had actual negative results, while eight patients had misleading negative results. In order to distinguish between benign and malignant ovarian masses using histopathology results as the gold standard, a 2x2 contingency table was created to estimate the sensitivity of 83.33%, specificity of 80.00%, PPV of

95.24%, NPV of 50%, and diagnostic accuracy of 82.76% of DWI MRI with ADC values. (Table-IV).



**Figure: ROC Curve Using ADC Value (AUC=0.914)**

**Table-IV: Assessment of DWI MRI accuracy in diagnosing malignant ovarian lesions, keeping histopathology as gold standard (n=58)**

DWI MRI	Histopathology	
	Benign (n=48)	Malignant (n=10)
Positive (n=42)	40 (83.3%)	2 (20%)
Negative (n=16)	8 (16.7%)	8 (80%)

DWI - Diffusion Weighted Imaging, MRI - Magnetic Resonance Imaging

## DISCUSSION

The study was conducted as Ovarian Cancer is now a growing global health issue and is becoming more common, particularly in lower socioeconomic areas. Timely diagnosis can optimize treatment plan. The findings of 58 subjects of the study. The mean age of the patients in this study was  $50.03 \pm 6.686$  years, and the bulk of them (84.5%) were between the ages of 40 and 60, with just 8.6% being under 40. The analysis determined that DWI and ADC have good specificity, which enhances the accuracy of imaging diagnostics.

According to research by Grabowska *et al.*,<sup>13</sup> the mean age for primary mucinous ovarian cancer, as determined by DWI MRI, was 55.5 years. The average BMI of the participants in our study was  $26.44 \pm 2.408 \text{ kg}/\text{m}^2$ . Only 3.4% of patients had a BMI over  $30 \text{ kg}/\text{m}^2$ , whereas 72.5% had a BMI between 25 and  $29.9 \text{ kg}/\text{m}^2$ . In their study, Fischerova *et al.*,<sup>14</sup> reported a mean BMI of  $26.5 \pm 5.5 \text{ kg}/\text{m}^2$ . In this cross-sectional study of 58 patients, 12.1% and 19% had a history of oligomenorrhea and pain, respectively. Our results were like those reported by Marrium *et al.*,<sup>15</sup> who found that the most common presenting complaints among patients with adnexal tumors were irregular menstrual periods and nonspecific abdominal/pelvic pain.

The ADC value of malignant tumours in this study was lower than that of benign tumours. It was deemed highly statistically significant with a *p*-value of 0.000. The area under the curve of the ROC curve was determined to be 0.914. In their study, Ali *et al.*,<sup>16</sup> examined 51 adult females with complex adnexal lesions, with the mean ADC value for ovarian malignancy being  $0.977 \times 10^{-3} \text{ mm}^2/\text{s} \pm 0.32$ . A value below  $1.17 \times 10^{-3} \text{ mm}^2/\text{s}$  indicated malignancy with 69.9% sensitivity and 75% specificity, while the area under the ROC curve was 0.756. A study by El Razeq *et al.*,<sup>17</sup> calculated that the mean ADC value of the benign ovarian masses  $1.6 \times 10^{-3} \text{ mm}^2/\text{s} \pm 0.27$ , whereas the value of malignant ovarian lesions was  $1.01 \times 10^{-3} \text{ mm}^2/\text{s} \pm 0.34$ . In our investigation, the DWI with ADC values' sensitivity, specificity, PPV, NPV, and diagnostic accuracy in identifying malignant ovarian tumours were 83.33%, 80.00%, 95.24%, 50%, and 82.76%, respectively. In order to determine the pooled sensitivity and specificity of DWI to distinguish between malignant and benign ovarian tumours, Yuan *et al.*,<sup>18</sup> carried out a meta-analysis that included 12 studies with 1142 individuals. The DWI specificity and sensitivity were 81% and 86%, respectively. 0.916 was the area under the curve. A study on the function of DWI MRI was carried out by Dawlat *et al.*,<sup>19</sup> confirmed that DWI's specificity was 78.6% and its sensitivity was 100%. According to Liu *et al.*,<sup>20</sup> research studies described that DWI MRI has an 81.2% diagnosis accuracy rate for ovarian cancer.

This exploration aims to investigate the important role of magnetic resonance imaging (MRI) in the diagnosis of ovarian cancer. The accuracy of diffusion weighted imaging (DWI) and apparent diffusion coefficient (ADC) value in diagnosing malignant ovarian lesions was determined.

#### LIMITATIONS OF STUDY

The small sample size of the single-centre investigation recommends that more randomised controlled trials with a comparatively higher sample size could establish trustworthy, valid, and reliable results in determining early diagnosis of Ovarian Cancer.

#### CONCLUSION

The study concluded that for accurate identification of malignant ovarian lesions, DWI and ADC values have good sensitivity, specificity, and accuracy. As a result, DWI with ADC value may develop into a potential method for ovarian cancer diagnosis, preoperative staging, and treatment, especially for patients with contraindications for contrast material.

#### ACKNOWLEDGEMENT

The department of gynaecology and histopathology assisted with data analysis, for which the authors are grateful.

**Conflict of Interest:** None.

**Funding Source:** None.

#### Authors' Contribution

Following authors have made substantial contributions to the manuscript as under:

TR & HRI: Data acquisition, data analysis, critical review, approval of the final version to be published.

NS & TR: Study design, data interpretation, drafting the manuscript, critical review, approval of the final version to be published.

HT: Conception, data acquisition, drafting the manuscript, approval of the final version to be published.

Authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

#### REFERENCES

1. Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz C, *et al.* Ovarian cancer statistics, 2018. *CA Cancer J Clin* 2018; 68(4): 284-296. <https://doi.org/10.3322/caac.21456>
2. Sohail I, Hayat Z, Saeed S. A Comparative Analysis of Frequency and Patterns of Ovarian Tumours at a Tertiary Care Hospital Between two Different Study Periods (2002-2009). *J Postgrad Med Inst [Internet]*. 2012 Mar. 23 [cited 2026; 26(2)]. Available from: <https://jpmi.org.pk/index.php/jpmi/article/view/1256>
3. Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: Evolution of management in the era of precision medicine. *CA: CA Cancer J Clin* 2019; 69(4): 280-304. <https://doi.org/10.3322/caac.21559>
4. Karpathiou G, Chauleur C, Hathroubi S, Peoc'h M. Secondary Tumors of the Gynecologic Tract: A Clinicopathologic Analysis. *Int J Gynecol Pathol* 2019; 38(4): 363-370. <https://doi.org/10.1097/pgp.0000000000000516>
5. Prader S, Vollmar N, du Bois A, Heitz F, Schneider S, Ataseven B, *et al.* Pattern and impact of metastatic cardiophrenic lymph nodes in advanced epithelial ovarian cancer. *Gynecol Oncol* 2019; 152(1): 76-81. <https://doi.org/10.1016/j.ygyno.2018.11.001>
6. Macchia G, Lazzari R, Colombo N, Lalischia C, Capelli G, D'Agostino GR, *et al.* A Large, Multicenter, Retrospective Study on Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups. *Oncologist* 2019; 25(2): e311-e320. <https://doi.org/10.1634/theoncologist.2019-0309>
7. Gagliardi T, Adejolu M, deSouza NM. Diffusion-Weighted Magnetic Resonance Imaging in Ovarian Cancer: Exploiting Strengths and Understanding Limitations. *J Clin Med* 2022; 11(6): 1524. <https://doi.org/10.3390/jcm11061524>
8. Bonde A, Andreatza Dal Lago E, Foster B, Javadi S, Palmquist S, Bhosale P. Utility of the Diffusion Weighted Sequence in Gynecological Imaging: Review Article. *Cancers* 2022; 14(18): 4468. <https://doi.org/10.3390/cancers14184468>

## Diagnosing Malignant Ovarian Lesions

9. Hagra AM, Elhawary TM, Hamisa M. Diagnostic accuracy of diffusion weighted imaging & dynamic contrast enhanced MRI in differentiating benign & malignant ovarian masses for optimum possible surgical strategies. *Fertility and Sterility*. 2018; 110(4): e132-133. <https://doi.org/10.1002/jmri.21575>
10. Forstner R. Early detection of ovarian cancer. *Eur Radiol* 2020; 30(10): 5370-5373. <https://doi.org/10.1007/s00330-020-06937-z>
11. Webb, Penelope, Jordan, Susan. Global epidemiology of epithelial ovarian cancer. *Nature Rev Clin Oncol* 2024; 21. <https://doi.org/10.1038/s41571-024-00881-3>
12. Nahm FS. Receiver operating characteristic curve: overview and practical use for clinicians. *Korean J Anesthesiol* 2022; 75(1): 25-36. <https://doi.org/10.4097/kja.21209>
13. Grabowska-Derlatka L, Derlatka P, Halaburda-Rola M. Characterization of Primary Mucinous Ovarian Cancer by Diffusion-Weighted and Dynamic Contrast Enhancement MRI in Comparison with Serous Ovarian Cancer. *Cancers* 2023; 15(5): 1453. <https://doi.org/10.3390/cancers15051453>
14. Fischerova D, Pinto P, Burgetova A, Masek M, Slama J, Kocian R, et al. Preoperative staging of ovarian cancer: comparison between ultrasound, CT and whole-body diffusion-weighted MRI (ISAAC study). *Ultrasound Obstet Gynecol* 2022; 59(2): 248-262. <https://doi.org/10.1002/uog.23654>
15. Marriam R, Shazmeera U, Sana F, Naima M, Chaudhary MAK, Muhammad UI. Diagnostic Accuracy of Transvaginal Versus Transabdominal Ultrasonography for Diagnosing Adnexal Masses. *Pak J Med Sci* 2022; 16(02): 1251. <https://doi.org/10.53350/pjmhs221621251>
16. Ali RF, Nassef HH, Ibrahim AM, Chalabi NAM, Mohamed AM. The Role of Diffusion Weighted Imaging in suspected cases of ovarian cancer. *Egypt J Radiol Nucl Med* 2020; 51: 1-11. <https://doi.org/10.1186/s43055-020-00213-2>
17. El Razeq GMA, Ahmed MAM. The Usefulness of Diffusion Weighted and Contrast Enhanced Magnetic Resonance Imaging in Characterization of Inconclusive Ovarian Mass. *Int J Med Phys Clin Eng Radiat Oncol* 2020; 09(01): 24-33. <https://doi.org/10.4236/ijmpcero.2020.91003>
18. Yuan X, Guo L, Du W, Mo F, Liu M. Diagnostic accuracy of DWI in patients with ovarian cancer: A meta-analysis. *Medicine* 2017; 96(19): e6659. <https://doi.org/10.1097/md.0000000000006659>
19. Dawlat A, Abd El-Mageed M, Naglaa S, Nermeen N, Keriakos MD. Role of DWI MRI as a Recent Modality in Differentiation between Benign from Malignant Ovarian Tumors. *Med J Cairo Univ* 2020; 88(12): 1699-1706. <https://doi.org/10.21608/mjcu.2020.116376>
20. Liu B, Liao J, Gu W, Wang J, Li G, Wang L. ADNEX Model-Based Diagnosis of Ovarian Cancer Using MRI Images. *Contrast Media Mol Imaging* 2021; 2021: 2146578. <https://doi.org/10.1155/2021/2146578>

.....